Stocks · Korea
069620
KOSPI
Daewoong Pharma
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-07 basis
PER6.49x
PBR1.26x
EPS17,022 KRW
BPS87,439 KRW
ROE17.21%
Dividend yield0.54%
DPS600 KRW
Payout ratio3.52%
Returns and 52-week range
1W+2.99%
1M-3.83%
3M-16.68%
6M-35.17%
1Y-21.98%
YTD-33.49%
52W high199,400원
52W low104,900원
From 52W high-44.63%
Financial results (consolidated)
| Period | Revenue | Operating income | Net income | OP margin |
|---|---|---|---|---|
| 2022 | 1.3조 | 958억 | 392억 | 7.5% |
| 2023 | 1.4조 | 1,226억 | 1,200억 | 8.9% |
| 2024 | 1.4조 | 1,479억 | 233억 | 10.4% |
| 2025 | 1.6조 | 1,968억 | 1,929억 | 12.5% |
| Quarterly | ||||
| 2024 4Q | 3,679억 | 387억 | -115억 | 10.5% |
| 2025 1Q | 3,565억 | 387억 | 198억 | 10.8% |
| 2025 2Q | 4,054억 | 579억 | 401억 | 14.3% |
| 2025 3Q | 4,118억 | 569억 | 473억 | 13.8% |
| 2025 4Q | 3,971억 | 433억 | 857억 | 10.9% |
| 2026 1Q | 3,778억 | 222억 | 255억 | 5.9% |
Company
Address: 경기도 화성시 향남읍 제약공단4길 35-14 -
Peers in the same sector
Recent filings
- 2026-08-14반기보고서 (2026.06)
- 2026-05-15분기보고서 (2026.03)
- 2026-03-18사업보고서 (2025.12)
- 2025-11-14분기보고서 (2025.09)
- 2025-08-14반기보고서 (2025.06)
- 2025-08-14[기재정정]사업보고서 (2024.12)
- 2025-05-15분기보고서 (2025.03)
Source: DART (Financial Supervisory Service electronic disclosure)
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.